Strategic advisor shaping the intellectual property landscape within biotech. With a firm commitment to innovation, my focus lies in developing robust IP creation and monetization strategies. Managing Director at Sauvegarder Investment Management, a multi-strategy investment firm dedicated to IP-related financing and investment opportunities including structured senior debt, structured equity, and high-value licensing and monetization campaigns. SIM invests across IP as an asset class and across jurisdictions, primarily focusing on the US, Europe and Israel.During my tenure at Valo Health I oversaw significant developments, such as the noted licensing deal with Novo Nordisk and the acquisition of Tara Biosystems, which brought in advanced tissue engineering and disease modeling tech. As a law-firm trial lawyer I handled a number of noteworthy cases from discovery through trial, including a jury verdict of patent infringement related to the preservation of soft tissue grafts resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets relating to Kevlar with damages of over $900 million, and the successful defense of The Regents of the University of California against a patent licensee seeking expanded rights of sponsored research and license agreements relating to compounds for the treatment of prostate cancer.I've been named one of the "Top 25 Women Leaders in Biotechnology of 2020" by The Healthcare Technology Report. National Law Journal “Rising Star" (40 under 40) in Washington, D.C. for 2015; profiled as a Law360 “Rising Star” in 2016; named to Law360’s 2016 Intellectual Property Editorial Advisory Board. Benchmark Litigation’s “Under 40 Hot List” in 2016 and 2017; and published in Bloomberg BNA Daily Report for Executives and the Intellectual Property & Technology Law Journal, among others.